AstraZeneca (AZN) Given a GBX 7,100 Price Target by JPMorgan Chase & Co. Analysts

AstraZeneca (LON:AZN) received a GBX 7,100 ($92.77) target price from investment analysts at JPMorgan Chase & Co. in a report released on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 13.76% from the stock’s current price.

AZN has been the topic of a number of other reports. Barclays restated an “overweight” rating on shares of AstraZeneca in a research note on Monday, January 21st. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Tuesday, January 1st. Societe Generale upped their target price on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a “buy” rating in a research note on Wednesday, January 16th. Cfra set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Friday, November 9th. Finally, Credit Suisse Group reiterated an “outperform” rating on shares of AstraZeneca in a research note on Monday, October 29th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca presently has an average rating of “Buy” and a consensus price target of GBX 6,222.20 ($81.30).

Shares of AZN stock opened at GBX 6,241 ($81.55) on Thursday. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: QQQ ETF

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.